Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Orphan drug market to reach $270 billion by 2028 despite decreasing growth rates
- According to data from Evaluate, the orphan drug market is projected to expand to $270 billion by 2028. This sector, while experiencing a deceleration in growth because of competitive pressures from treatments for common ailments and heightened scrutiny of pricing strategies, continues to be a significant contributor to the pharmaceutical industry’s development.
- The competitive dynamics are also evolving, with new entries disrupting the rankings of established best-sellers.
Empowering women leaders at Biotech Sisterhood summit
- The third annual summit of the Biotech Sisterhood convened to offer support and networking for women leaders in the biotech industry, reports Fierce Biotech.
- The summit serves as a platform to support and empower women in the biotech industry, focusing on leadership, community-building and the importance of diversity in executive roles.
FDA’s initiative to integrate medical devices at home
- The Food and Drug Administration’s “Home as a Health Care Hub” initiative emphasizes integrating advanced medical devices into home settings to enhance health care delivery and equity. This approach particularly targets the use of home-based medical technologies to manage chronic conditions efficiently, making health care more accessible, especially in underserved areas.
- The initiative views homes as pivotal in extending health care’s reach through technological integration.
Impact of news on biopharma stock prices: Event study
- This article from MIT researchers explores how news impacts biopharmaceutical stock prices, using an event study of over 500,000 news releases across 1,012 companies. It finds that acquisition news typically generates positive stock returns.
- The study highlights larger volatility in biotechnology stocks compared to pharmaceuticals, which are more affected by broader financial news. The findings aim to guide stakeholders in making informed decisions in the volatile biopharmaceutical market.
Fujifilm’s $1.2 billion investment in North Carolina
- Fujifilm Diosynth has announced another expansion with an investment of approximately $1.2 billion to open an end-to-end biomanufacturing facility, reports Fierce Pharma. This time, the investment will take place in North Carolina’s Research Triangle Park.
- This follows billions of dollars of investment made by Fujifilm in recent years across several regions of the world.
For more insights in life sciences, check out RSM’s industry outlook.
